Cargando…

Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia – A Randomized Controlled Trial

BACKGROUND: Androgenetic alopecia (AGA) is caused by the susceptibility of hair follicles to androgenic miniaturization, which leads to hair loss. The most common modalities for the treatment of AGA include the use of topical minoxidil and oral finasteride. Low-level laser therapy (LLLT) is a newer...

Descripción completa

Detalles Bibliográficos
Autores principales: Sondagar, Dharm Mansukh, Mehta, Hita H., Agharia, Rashmiben Sabbirali, Jhavar, Milan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251294/
https://www.ncbi.nlm.nih.gov/pubmed/37305186
http://dx.doi.org/10.4103/ijt.ijt_5_22
_version_ 1785055916143411200
author Sondagar, Dharm Mansukh
Mehta, Hita H.
Agharia, Rashmiben Sabbirali
Jhavar, Milan K.
author_facet Sondagar, Dharm Mansukh
Mehta, Hita H.
Agharia, Rashmiben Sabbirali
Jhavar, Milan K.
author_sort Sondagar, Dharm Mansukh
collection PubMed
description BACKGROUND: Androgenetic alopecia (AGA) is caused by the susceptibility of hair follicles to androgenic miniaturization, which leads to hair loss. The most common modalities for the treatment of AGA include the use of topical minoxidil and oral finasteride. Low-level laser therapy (LLLT) is a newer modality of treatment for AGA. We tried to evaluate the added benefit of LLLT in AGA compared with topical minoxidil 5% alone. AIM: The aim of this study was to compare the efficacy of LLLT combined with topical 5% minoxidil in AGA versus topical 5% minoxidil used alone. MATERIALS AND METHODS: After ethics committee approval, 54 patients of AGA were randomly divided into two groups. Group A participants received LLLT therapy twice a week plus topical 5% minoxidil and Group B participants received only minoxidil 5% solution. Both the groups were followed up for 16 weeks and evaluated with gross photographs, TrichoScan analysis, and dermoscopy to look for any improvement in hair density. RESULTS: After 16 weeks, improvement in hair density of 14.78% ± 10.93% in Group A was recorded compared to 11.43% ± 6.43% in Group B. However, while comparing both means, P value was 0.45 which was not significant. The physician global assessment and patient satisfaction score revealed no significant difference between both the groups. CONCLUSION: Although LLLT appears to be safe and effective in the treatment of male pattern hair loss, we did not observe any significant difference in terms of improvement in hair density between both the groups.
format Online
Article
Text
id pubmed-10251294
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-102512942023-06-10 Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia – A Randomized Controlled Trial Sondagar, Dharm Mansukh Mehta, Hita H. Agharia, Rashmiben Sabbirali Jhavar, Milan K. Int J Trichology Original Article BACKGROUND: Androgenetic alopecia (AGA) is caused by the susceptibility of hair follicles to androgenic miniaturization, which leads to hair loss. The most common modalities for the treatment of AGA include the use of topical minoxidil and oral finasteride. Low-level laser therapy (LLLT) is a newer modality of treatment for AGA. We tried to evaluate the added benefit of LLLT in AGA compared with topical minoxidil 5% alone. AIM: The aim of this study was to compare the efficacy of LLLT combined with topical 5% minoxidil in AGA versus topical 5% minoxidil used alone. MATERIALS AND METHODS: After ethics committee approval, 54 patients of AGA were randomly divided into two groups. Group A participants received LLLT therapy twice a week plus topical 5% minoxidil and Group B participants received only minoxidil 5% solution. Both the groups were followed up for 16 weeks and evaluated with gross photographs, TrichoScan analysis, and dermoscopy to look for any improvement in hair density. RESULTS: After 16 weeks, improvement in hair density of 14.78% ± 10.93% in Group A was recorded compared to 11.43% ± 6.43% in Group B. However, while comparing both means, P value was 0.45 which was not significant. The physician global assessment and patient satisfaction score revealed no significant difference between both the groups. CONCLUSION: Although LLLT appears to be safe and effective in the treatment of male pattern hair loss, we did not observe any significant difference in terms of improvement in hair density between both the groups. Medknow Publications & Media Pvt Ltd 2023 2023-04-19 /pmc/articles/PMC10251294/ /pubmed/37305186 http://dx.doi.org/10.4103/ijt.ijt_5_22 Text en Copyright: © 2023 International Journal of Trichology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Sondagar, Dharm Mansukh
Mehta, Hita H.
Agharia, Rashmiben Sabbirali
Jhavar, Milan K.
Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia – A Randomized Controlled Trial
title Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia – A Randomized Controlled Trial
title_full Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia – A Randomized Controlled Trial
title_fullStr Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia – A Randomized Controlled Trial
title_full_unstemmed Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia – A Randomized Controlled Trial
title_short Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia – A Randomized Controlled Trial
title_sort efficacy of low-level laser therapy in androgenetic alopecia – a randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251294/
https://www.ncbi.nlm.nih.gov/pubmed/37305186
http://dx.doi.org/10.4103/ijt.ijt_5_22
work_keys_str_mv AT sondagardharmmansukh efficacyoflowlevellasertherapyinandrogeneticalopeciaarandomizedcontrolledtrial
AT mehtahitah efficacyoflowlevellasertherapyinandrogeneticalopeciaarandomizedcontrolledtrial
AT aghariarashmibensabbirali efficacyoflowlevellasertherapyinandrogeneticalopeciaarandomizedcontrolledtrial
AT jhavarmilank efficacyoflowlevellasertherapyinandrogeneticalopeciaarandomizedcontrolledtrial